Onkologie. 2013:7(3):117-120

Chronic lymphocytic leukemia - diagnosis and treatment

Anna Panovská, Michael Doubek
Interní hematoonkologická klinika, FN a LF MU Brno

Chronic lymphocytic leukemia (CLL) is a low-grade lymphoma, typically found in eldery people. CLL is the most common leukemia in the

Western World, it makes up almost 30% of all leukemias. Pathogenesis of CLL is still unknown, however, an antigen stimulation, apoptotic

defects and the role of microenvironment are often discussed. At present, new prognostic factors are being analyzed in order to define

a risk subgroup of patients that would benefit from early and intensive start of therapy. Treatment of CLL has made a great progress in the

last decade. While a few years ago chlorambucil was a golden standard in the CLL therapy, currently, the combination of a chemotherapy

backbone with the monoclonal antibody has opened up new horizons for CLL therapy. Patients treated with chemoimmunotherapy can

achieve years of complete remission of CLL. Allogeneic stem cell transplantation still represents the only curative approach.

Keywords: chronic lymphocytic leukemia, epidemiology, prognostic factors, chemoimmunotherapy, allogeneic stem cell transplantation

Published: July 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Panovská A, Doubek M. Chronic lymphocytic leukemia - diagnosis and treatment. Onkologie. 2013;7(3):117-120.
Download citation

References

  1. Hallek M, Cheson BD, Catovsky D, et al. Guidlines for the diagnostic and treatment of chronic lymphocytic leukaemia: a report from the International Workshop on Chronic Lymphocytic Leukaemia updating the National Cancer Institute-Working Group 1996 guidlines. Blood 2008; 111: 5446-5456. Go to original source... Go to PubMed...
  2. National Cancer Institute. "Chronic Lymphocytic Leukemia (PDQ) Treatment: Stage information". http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page2.
  3. Doubek M, Panovská A, Janča J, et al. Co víme o incidence chronické lymfatické leukemie (CLL), a kde a jak jsou nemocní s CLL léčeni? Transfuze Hematol. dnes, 2010; 16(Suppl. 1): 11-15.
  4. Buliková A, Kissová J, Trnavská I, et al. Cytologické morfologické nálezy u chronické lymfocytární leukemie a diferenciální diagnostika lymfocytóz v periferní krvi. Transfuze Hematol. Dnes, 2010; 16(Suppl 1): 36-44. Go to original source...
  5. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and Survival in Chronic Lymphocytic Leukemia. N Engl J Medicine 2000; 343: 1910-1916. Go to original source... Go to PubMed...
  6. Malciková J, Smardová J, Rocnová L, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage. Blood 2009; 114: 5307-5314. Go to original source... Go to PubMed...
  7. Dighiero G, Maloum K, Desamblens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med, 1998; 338: 1506-1514. Go to original source... Go to PubMed...
  8. Rai KR, Peterson PL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med, 2000; 343: 1750-1757. Go to original source... Go to PubMed...
  9. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomized, open-label, phase 3 trial. Lancet 2010; 376(9747): 1164-1174. Go to original source... Go to PubMed...
  10. Osterborg A, Kipps T, Mayer J, et al. Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. Blood (ASH Annual Meeting Abstracts), 2008; 122: 328a. Go to original source...
  11. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 2002; 99: 3554-3561. Go to original source... Go to PubMed...
  12. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119(5): 1182-1189. Go to original source... Go to PubMed...
  13. Dreger P, Brand R, Milligan D, et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005; 19: 1029-1033. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.